Table 1.
Currently approved checkpoint inhibitors
| Drug name | Target | Manufacturer | Approved disease site |
|---|---|---|---|
| Ipilimumab | CTLA-4 | Bristol-Meyers Squibb | Melanoma RCCa |
| Pembrolizumab | PD-1 | Merck | Melanoma NSCLC HNSCC HL PMBCL Urothelial carcinoma MSI-H/dMMR Solid Tumors Gastric Cancer Cervical Cancer |
| Nivolumab | PD-1 | Bristol-Meyers Squibb | Melanoma RCC NSCLC HNSCC HL Urothelial carcinoma Colorectal cancer HCC |
| Avelumab | PD-L1 | Merck/Pfizer | Merkel cell carcinoma RCC* Urothelial carcinoma |
| Durvalumab | PD-L1 | Astra Zeneca | Urothelial carcinoma NSCLC |
| Atezolizumab | PD-L1 | Genentech | Urothelial carcinoma NSCLC |
RCC renal cell cancer, NSCLC non-small cell lung cancer, HNSCC head and neck squamous cell carcinoma, HL Hodgkin lymphoma (classic), PMBCL primary mediastinal B cell lymphoma, MSI-H microsatellite instability high, dMMR mismatch repair gene deficient, HCC hepatocellular carcinoma
aApproval granted for use in combination with another therapeutic agent